Mounjaro® Price Hike from September 2025 – What It Means for You

Mounjaro® Price Hike from September 2025 – What It Means for You

Eli Lilly, the manufacturer of Mounjaro® (tirzepatide), has recently announced a significant price increase effective 1st September 2025. Understandably, this news has caused concern among many private users who rely on the medication for weight loss

At eMeds Pharmacy, we’re committed to supporting our patients through this change by providing transparent guidance, accessible alternatives, and affordable pricing where possible.

 Why Has Mounjaro® Become More Expensive?

The exact reasons behind the Mounjaro® price increase have not been officially detailed, but it likely reflects rising global demand, production costs, and regulatory dynamics. While the price hike affects all UK private users, the real burden falls on individuals funding their treatment out-of-pocket.

Private users are, in fact, helping to reduce long-term strain on the NHS by proactively managing their weight and metabolic health. Many feel disheartened by the financial barrier this sudden change presents.

Considering a Switch to Wegovy®?

In light of the price hike, some patients are exploring alternatives like Wegovy® (semaglutide). While both Mounjaro and Wegovy belong to the GLP-1 receptor agonist family, they differ in dosing, efficacy, and side effect profiles. Switching between them is not a decision to be taken lightly.

It’s crucial to consult with a qualified prescriber—whether a pharmacist, nurse, or GP—before making any changes. At eMeds Pharmacy, we ensure each treatment plan is tailored specifically to the individual’s health history and progress.

Will the New Prices Be Manageable?

There’s a silver lining: pharmacies have been offered slight reductions on the originally proposed wholesale prices. While these aren’t dramatic discounts, they may allow some pharmacies to pass limited savings onto patients.

As a small independent pharmacy, we understand the pressures of affordability. That’s why we are working hard to minimise the financial impact for our loyal customers who are using our specialist weight loss Mounjaro and Wegovy service.

Be Cautious of Misleading Online Advertising

Following the price change announcement, the General Pharmaceutical Council (GPhC) issued a warning on 29th July 2025 about inappropriate marketing of GLP-1 medications like Mounjaro®. Some online pharmacies are aggressively promoting weight-loss medicines without proper medical oversight, which can put patient safety at risk.

Make sure that:

• Your treatment is prescribed by a professional.

• Your full medical history and current response to treatment are considered.

• You are being monitored for side effects and progress.

Safe & Professional Online Consultations with eMeds Pharmacy

At eMeds Pharmacy, your safety is our priority. All prescriptions for Mounjaro® or similar weight-loss treatments are issued only after a comprehensive review by our qualified healthcare professionals.

Our team will:

• Review your health records and medication history.
• Assess your suitability based on your weight loss progress and any side effects.
• Ensure the treatment is safe and appropriate for your individual needs.

We don’t rely on questionnaires alone. Our consultations involve genuine clinical judgment and care. If you have questions about the price increase or your treatment, reach out to our support team—we’re just a click away.